Tcr2 Therapeutics OverviewTcr2 Therapeutics EBIT
EBIT (Earnings Before Interest and Taxes) analysis for TCRR.
Quarterly EBIT
-$41.51M
↓ 42.13% YoY
As of Mar 31, 2023
Annual EBIT (TTM)
-$165.80M
↓ 54.6% YoY
Trailing 12 months ending Mar 31, 2023
Tcr2 Therapeutics OverviewEBIT (Earnings Before Interest and Taxes) analysis for TCRR.
As of Mar 31, 2023
Trailing 12 months ending Mar 31, 2023